Skip to main content
GENEMATRIX INC. logo

GENEMATRIX INC. — Investor Relations & Filings

Ticker · 109820 ISIN · KR7109820001 KO Manufacturing
Open in API
Filings indexed 175 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 109820

About GENEMATRIX INC.

https://genematrix.net/en

GENEMATRIX INC. is a biotechnology company that develops molecular diagnostic products and promotes new drug development. The company specializes in multiplex real-time PCR technology, which enables the simultaneous detection of multiple pathogens in a single test. Its core product line, NeoPlex™, offers a range of diagnostic assays for infectious diseases, including comprehensive panels for respiratory viruses and bacteria, human papillomavirus (HPV), and tuberculosis. GENEMATRIX focuses on creating innovative platform technologies to advance diagnostics and is also expanding into AI-powered solutions for precision medicine.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is a detailed "분기보고서" (Korean quarterly report) covering the first quarter (Jan 1 to Mar 31, 2026) of the 27th fiscal term. It includes comprehensive financial statements, operational and business overviews, capital changes, asset schedules and other substantive data. It is not merely an announcement or certification but the full quarterly report itself. Therefore, it matches the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled “정기주주총회결과” (Annual General Meeting Results) and provides detailed voting outcomes for each proposal (agenda items, vote counts, percentages, approval status), director elections, and dividend resolutions. This matches the definition of “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-03-26 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Genematrix Inc. (주)진매트릭스, covering the fiscal year 2025 (2025-01-01 to 2025-12-31). It contains comprehensive company information, including business overview, financial data, capital structure, and management details. In the South Korean regulatory context, the 'Business Report' (사업보고서) is the equivalent of the US 10-K Annual Report, as it is the primary annual disclosure document filed with the Financial Supervisory Service (FSS) and the Korea Exchange (KRX). FY 2025
2026-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion, key financial data, and auditor information for the fiscal year ending 2025-12-31. While it contains financial data, it is a standardized regulatory disclosure form announcing the receipt and filing of the audit report rather than the full, multi-page audit report document itself. Therefore, it falls under the category of Audit Report / Information (AR). FY 2025
2026-03-18 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by GeneMatrix. It outlines the date, location, agenda items (such as approval of financial statements, election of directors, and remuneration limits), and details regarding electronic voting. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2026-02-25 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Genematrix. It contains the agenda for the 26th Annual General Meeting, including financial statement approval, director appointments, and remuneration limits. In the context of financial filings, documents that serve as the official notice and proxy materials for an upcoming shareholder meeting are classified as Proxy Solicitation & Information Statements.
2026-02-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.